Breaking News

Moberg Pharma and Cadila Enter Agreement

Together will work towards late-stage development and commercialization of BUPI

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Moberg Pharma and Cadila Pharmaceuticals, one of the largest healthcare manufacturing groups in India, entered a development and license agreement for BUPI, a lozenge formulation of bupivacaine for pain management in oral mucositis patients. Cadila will conduct a phase III program in India and is granted an exclusive license to commercialize BUPI in India and Africa, with the exception of South Africa. Moberg will receive the rights to use all data generated from the development program outsi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters